Cutaneous Lupus Erythematosus: Progress and Challenges

被引:27
|
作者
Petty, Amy J. [1 ]
Floyd, Lauren [2 ]
Henderson, Christopher [2 ]
Nicholas, Matilda W. [2 ]
机构
[1] Duke Univ, Sch Med, Durham, NC 27710 USA
[2] Duke Univ, Dept Dermatol, Durham, NC 27710 USA
关键词
Cutaneous lupus erythematosus; Systemic lupus erythematosus; Drug-induced lupus erythematosus; Management; DOUBLE-BLIND; DISEASE AREA; CLASSIFICATION CRITERIA; MYCOPHENOLATE-MOFETIL; ULTRAVIOLET-RADIATION; CLOBETASOL PROPIONATE; SEVERITY INDEX; EFFICACY; THALIDOMIDE; SAFETY;
D O I
10.1007/s11882-020-00906-8
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Purpose of Review The review provides an update on the diagnosis, pathogenesis, and treatment of cutaneous lupus erythematosus (CLE). Recent Findings Diagnostic challenges exist in better defining CLE as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials. CLE is a group of complex and heterogenous diseases. Future studies are warranted to better define CLE within the spectrum of lupus erythematosus. Better insight into the pathogenesis of CLE could facilitate the design of more targeted therapies.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Linear cutaneous lupus erythematosus: a subset of childhood cutaneous lupus erythematosus
    Gaitanis, G.
    Nomikos, K.
    Chaniotakis, I.
    Stergiopoulou, C.
    Zioga, A.
    Bassukas, I.
    LUPUS, 2009, 18 (08) : 759 - 761
  • [32] Innovations in Cutaneous Lupus
    Lin, Rachel R.
    Warp, Peyton, V
    Hartoyo, Mara A.
    Elman, Scott A.
    Maderal, Andrea D.
    DERMATOLOGIC CLINICS, 2025, 43 (01) : 123 - 136
  • [33] Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
    Josefina Cortés-Hernández
    Gabriela Ávila
    Miquel Vilardell-Tarrés
    Josep Ordi-Ros
    Arthritis Research & Therapy, 14
  • [34] Drugs for discoid lupus erythematosus
    Jessop, Sue
    Whitelaw, David A.
    Grainge, Matthew J.
    Jayasekera, Prativa
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (05):
  • [35] Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis
    Oke, V.
    Wahren-Herlenius, M.
    JOURNAL OF INTERNAL MEDICINE, 2013, 273 (06) : 544 - 554
  • [36] Candidate drug replacements for quinacrine in cutaneous lupus erythematosus
    Yan, Daisy
    Borucki, Robert
    Sontheimer, Richard D.
    Werth, Victoria P.
    LUPUS SCIENCE & MEDICINE, 2020, 7 (01):
  • [37] Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus
    Soto, Jorge A.
    Melo-Gonzalez, Felipe
    Riedel, Claudia A.
    Bueno, Susan M.
    Kalergis, Alexis M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [38] Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment
    Hejazi, Emily Z.
    Werth, Victoria P.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (02) : 135 - 146
  • [39] The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review
    Fijalkowska, Aleksandra
    Kadziela, Marcelina
    Zebrowska, Agnieszka
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (08)
  • [40] Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review
    Chasset, Francois
    Frances, Camille
    DRUGS, 2019, 79 (11) : 1199 - 1215